A comparison of the effect on dispersion of repolarization of age-adjusted MAC values of sevoflurane in children

Anesthesia and Analgesia

Volumn 104, Issue 2, 2007, Pages 277-282

  Whyte, Simon D ^a,b   Sanatani, Shubhayan ^a,b   Lim, Joanne ^a,b   Booker, Peter D ^c,d  

^a BC CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c ALDER HEY CHILDREN S HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

SEVOFLURANE;

AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFECT; ELECTROCARDIOGRAPHY MONITORING; FEMALE; HEART REPOLARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; T WAVE AMPLITUDE;

AGE FACTORS; CHILD; CHILD, PRESCHOOL; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; LONG QT SYNDROME; MALE; METHYL ETHERS; TORSADES DE POINTES;

EID: 33846442395     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000252417.23986.6e     Document Type: Article

References (46)

1. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920;7:353-70.
2. Davignon A, Rautahaju P, Boiselle E, et al. Normal ECG standards for infants and children. Pediatr Cardiol 1979;1:123-31.
3. Ackerman MJ. The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc 1998;73:250-69.
4. www.torsades.org.
5. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993;87:1866-72.
6. Yan GX, Antzelevitch C. Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 1998;98:1928-36.
7. Shimizu W, Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 1997;96:2038-47.
8. Shimizu W, Antzelevitch C. Differential effects of β-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol 2000;35:778-86.
9. Shimizu W, Antzelevitch C. Cellular basis for the ECG features of the LQT1 form of the long-QT syndrome: effects of β-adrenergic agonists and antagonists and sodium channel blockers on transmural dispersion of repolarization and torsade de pointes. Circulation 1998;98:2314-22.
10. Whyte SD, Booker PD, Buckley DG. The effects of propofol and sevoflurane on the QT interval and transmural dispersion of repolarization in children. Anesth Analg 2005;100:71-7.
11. Antzelevitch C, Shimizu W, Yan GX, Sicouri S. Cellular basis for QT dispersion. J Electrocardiol 1998;30(Suppl):168-75.
12. Antzelevitch C, Shimizu W, Yan GX, et al. The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol 1999;10:1124-52.
13. Schmeling WT, Warltier DC, McDonald DJ, et al. Prolongation of the QT interval by enflurane, isoflurane, and halothane in humans. Anesth Analg 1991;72:137-44.
14. Michaloudis D, Fraidakis O, Lefaki T, et al. Anaesthesia and the QT interval in humans. The effects of isoflurane and halothane. Anaesthesia 1996;51:219-24.
15. Michaloudis D, Fraidakis O, Lefaki T, Kanakoudis F, Askitopoulou H. Anaesthesia and the QT interval in humans: effects of halothane and isoflurane in premedicated children. Eur J Anaesthesiol 1998;15:623-8.
16. Kuenszberg E, Loeckinger A, Kleinsasser A, et al. Sevoflurane progressively prolongs the QT interval in unpremedicated female adults. Eur J Anaesthesiol 2000;17:662-4.
17. Loeckinger A, Kleinsasser A, Maier S, et al. Sustained prolongation of the QTc interval after anesthesia with sevoflurane in infants during the first 6 months of life. Anesthesiology 2003;98:639-42.
18. Kleinsasser A, Kuenszberg E, Loeckinger A, et al. Sevoflurane, but not propofol, significantly prolongs the Q-T interval. Anesth Analg 2000;90:25-7.
19. Kleinsasser A, Loeckinger A, Lindner KH, et al. Reversing sevoflurane-associated Q-Tc prolongation by changing to propofol. Anaesthesia 2001;56:248-50.
20. Gallagher JD, Weindling SN, Anderson G, Fillinger MP. Effects of sevoflurane on QT interval in a patient with congenital long QT syndrome. Anesthesiology 1998;89:1569-73.
21. Nickalls RW, Mapelson WW. Age-related iso-MAC charts for isoflurane, sevoflurane and desflurane in man. Br J Anaesth 2003;91:170-4.
22. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952;6:378-88.
23. Benatar A, Cools F, Decraene T, et al. The T wave as a marker of dispersion of ventricular repolarization in premature infants before and while on treatment with the I(Kr) channel blocker cisapride. Cardiol Young 2002;12:32-6.
24. Lubinski A, Lewicka-Nowak E, Kempa M, et al. New insight into repolarization abnormalities in patients with congenital long QT syndrome: the increased transmural dispersion of repolarization. Pacing Clin Electrophysiol 1998;21:172-5.
25. Lawrence CL, Pollard CE, Hammond TG, Valentin JP. Nonclinical proarrhythmia models: predicting Torsades de Pointes. J Pharmacol Toxicol Methods 2005;52:46-59.
26. Yamaguchi M, Shimizu M, Ino H, et al. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: a new index for arrhythmogenicity. Clin Sci (Lond) 2003;105:671-6.
27. Tanabe Y, Inagaki M, Kurita T, et al. Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2001;37:911-19.
28. Shimizu W, Tanabe Y, Aiba T, et al. Differential effects of β-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol 2002;39:1984-91.
29. Saussine M, Massad I, Raczka F, et al. Torsade de pointes during sevoflurane anesthesia in a child with congenital long QT syndrome. Paediatr Anaesth 2006;16:63-5.
30. Antzelevitch C, Fish J. Electrical heterogeneity within the ventricular wall. Basic Res Cardiol 2001;96:517-27.
31. Gallagher JD. Effects of halothane and quinidine on intracardiac conduction and QTc interval in pentobarbital-anesthetized dogs. Anesth Analg 1992;75:688-95.
32. Lindgren L. ECG changes during halothane and enflurane anaesthesia for ENT surgery in children. Br J Anaesth 1981;53:653-62.
33. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 2000;11:290-304.
34. Adu-Gyamfi Y, Said A, Chowdhary UM, et al. Anaesthetic-induced ventricular tachyarrhythmia in Jervell and Lange-Nielsen syndrome. Can J Anaesth 1991;38:345-6.
35. Holland JJ. Cardiac arrest under anaesthesia in a child with previously undiagnosed Jervell and Lange-Nielsen syndrome. Anaesthesia 1993;48:149-51.
36. Wig J, Bali IM, Singh RG, et al. Prolonged Q-T interval syndrome. Sudden cardiac arrest during anaesthesia. Anaesthesia 1979;34:37-40.
37. Park WK, Pancrazio JJ, Suh CK, Lynch C III. Myocardial depressant effects of sevoflurane. Mechanical and electrophysiologic actions in vitro. Anesthesiology 1996;84:1166-76.
38. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
39. Abbott GW, Sesti F, Splawski I, et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-87.
40. Escande D. Pharmacogenetics of cardiac K(+) channels. Eur J Pharmacol 2000;410:281-7.
41. Xia Y, Liang Y, Kongstad O, et al. T(peak)-T(end) interval as an index of global dispersion of ventricular repolarization: evaluations using monophasic action potential mapping of the epi-and endocardium in swine. J Interv Card Electrophysiol 2005;14:79-87.
42. Van Huysduynen BH, Swenne CA, Draisma HH, et al. Validation of ECG indices of ventricular repolarization heterogeneity: a computer simulation study. J Cardiovasc Electrophysiol 2005;16:1097-103.
43. Chevalier P, Rodriguez C, Bontemps L, et al. Non-invasive testing of acquired long QT syndrome: evidence for multiple arrhythmogenic substrates. Cardiovasc Res 2001;50:386-98.
44. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002;105:1943-8.
45. Kannankeril PJ, Roden DM, Norris KJ, et al. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm 2005;2:134-40.
46. Aiba T, Shimizu W, Inagaki M, et al. Cellular and ionic mechanism for drug-induced long QT syndrome and effectiveness of verapamil. J Am Coll Cardiol 2005;45:300-7.